News 2022-03-02
Porton Plans to Invest 420 million to Expand CDMO Production Capacity of Small Molecule API
March 1st, 2022, Chongqing · China – Porton Pharma Solutions Ltd. announced an investment of 420 million to expand CDMO Production Capacity of Small Molecule API in Porton Pharma (Jiangxi) Co., Ltd. which is mainly engaged in customized production of APIs, intermediates and starting materials.
This expansion project will add 2 production workshops, utilities workshop, comprehensive warehouses and other facilities, which total construction area is 31,270㎡. With an estimated new production capacity of 300 m3, it is planned to be completed and put into operation by the end of 2023. In the future, Porton will undertake more high value-added intermediates and API production projects, which will help further consolidate the company's comprehensive capabilities as an End-to-End CDMO service platform.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
